Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 13 | 2025 | 331 | 2.370 |
Why?
|
| Caenorhabditis elegans | 8 | 2024 | 135 | 1.190 |
Why?
|
| Interleukin-1beta | 3 | 2025 | 87 | 1.050 |
Why?
|
| Molecular Dynamics Simulation | 4 | 2020 | 44 | 0.850 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2024 | 225 | 0.840 |
Why?
|
| Indans | 2 | 2020 | 7 | 0.770 |
Why?
|
| Signal Transduction | 6 | 2025 | 1699 | 0.730 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2020 | 170 | 0.720 |
Why?
|
| Thiadiazoles | 1 | 2020 | 18 | 0.670 |
Why?
|
| Ubiquitination | 1 | 2019 | 57 | 0.630 |
Why?
|
| Neurodegenerative Diseases | 4 | 2025 | 81 | 0.620 |
Why?
|
| Caenorhabditis elegans Proteins | 2 | 2018 | 59 | 0.600 |
Why?
|
| Proteins | 2 | 2018 | 347 | 0.590 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 136 | 0.580 |
Why?
|
| Apolipoprotein E4 | 3 | 2025 | 22 | 0.580 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 136 | 0.550 |
Why?
|
| Replication Origin | 1 | 2017 | 11 | 0.540 |
Why?
|
| RNA, Transfer | 1 | 2017 | 13 | 0.540 |
Why?
|
| Telomerase | 1 | 2017 | 26 | 0.540 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 114 | 0.500 |
Why?
|
| DNA Replication | 1 | 2017 | 159 | 0.500 |
Why?
|
| Molecular Docking Simulation | 6 | 2023 | 88 | 0.470 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 1214 | 0.420 |
Why?
|
| Autophagy | 4 | 2025 | 195 | 0.410 |
Why?
|
| Animals | 16 | 2025 | 13332 | 0.400 |
Why?
|
| Glioblastoma | 2 | 2025 | 96 | 0.400 |
Why?
|
| Hippocampus | 3 | 2025 | 193 | 0.350 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 287 | 0.350 |
Why?
|
| Models, Molecular | 4 | 2019 | 351 | 0.340 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2023 | 33 | 0.340 |
Why?
|
| Protein Conformation | 3 | 2020 | 177 | 0.340 |
Why?
|
| Lysosomes | 2 | 2024 | 70 | 0.340 |
Why?
|
| Ubiquitin | 3 | 2019 | 68 | 0.330 |
Why?
|
| Neoplasms | 1 | 2020 | 1288 | 0.320 |
Why?
|
| Mice | 6 | 2025 | 5877 | 0.310 |
Why?
|
| Mitochondria | 2 | 2025 | 421 | 0.300 |
Why?
|
| Humans | 28 | 2025 | 52114 | 0.300 |
Why?
|
| Sesquiterpenes | 2 | 2021 | 92 | 0.300 |
Why?
|
| NF-kappa B | 2 | 2021 | 329 | 0.280 |
Why?
|
| Brain | 3 | 2023 | 1311 | 0.280 |
Why?
|
| Phosphatidylinositol Phosphates | 2 | 2018 | 17 | 0.270 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2025 | 49 | 0.260 |
Why?
|
| Aging | 2 | 2025 | 701 | 0.250 |
Why?
|
| Protein Binding | 5 | 2018 | 665 | 0.240 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2018 | 138 | 0.240 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2025 | 17 | 0.240 |
Why?
|
| Binding Sites | 3 | 2021 | 375 | 0.230 |
Why?
|
| 14-3-3 Proteins | 2 | 2022 | 18 | 0.230 |
Why?
|
| Catalytic Domain | 2 | 2020 | 60 | 0.200 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2022 | 6 | 0.200 |
Why?
|
| Profilins | 2 | 2023 | 14 | 0.200 |
Why?
|
| Apoptosis | 2 | 2020 | 1117 | 0.200 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 86 | 0.190 |
Why?
|
| Cell Line, Tumor | 6 | 2025 | 1418 | 0.190 |
Why?
|
| Cell Line | 3 | 2020 | 1018 | 0.180 |
Why?
|
| Benzylamines | 1 | 2021 | 14 | 0.180 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 25 | 0.180 |
Why?
|
| Peptide Chain Elongation, Translational | 1 | 2021 | 5 | 0.180 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 566 | 0.170 |
Why?
|
| Alkaloids | 1 | 2021 | 34 | 0.170 |
Why?
|
| Phosphorylation | 5 | 2021 | 523 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 101 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2020 | 19 | 0.160 |
Why?
|
| HL-60 Cells | 1 | 2020 | 19 | 0.160 |
Why?
|
| Allosteric Regulation | 1 | 2020 | 16 | 0.160 |
Why?
|
| RNA | 1 | 2021 | 169 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 86 | 0.160 |
Why?
|
| beta-Lactamases | 1 | 2019 | 17 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 493 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 445 | 0.160 |
Why?
|
| Cell Proliferation | 5 | 2025 | 1017 | 0.150 |
Why?
|
| Protein Transport | 1 | 2019 | 166 | 0.150 |
Why?
|
| Enzyme Activation | 1 | 2019 | 269 | 0.150 |
Why?
|
| Oligopeptides | 1 | 2019 | 92 | 0.150 |
Why?
|
| Mutation | 3 | 2023 | 1318 | 0.150 |
Why?
|
| Protein Unfolding | 1 | 2018 | 7 | 0.150 |
Why?
|
| Structure-Activity Relationship | 4 | 2021 | 404 | 0.150 |
Why?
|
| Somatomedins | 1 | 2018 | 30 | 0.150 |
Why?
|
| Tetrazoles | 1 | 2018 | 41 | 0.150 |
Why?
|
| DNA | 1 | 2021 | 543 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2018 | 328 | 0.140 |
Why?
|
| Triazoles | 1 | 2018 | 113 | 0.140 |
Why?
|
| Nucleotide Motifs | 1 | 2017 | 22 | 0.140 |
Why?
|
| Computational Biology | 1 | 2018 | 209 | 0.130 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2016 | 10 | 0.130 |
Why?
|
| Muscles | 1 | 2016 | 108 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 1534 | 0.120 |
Why?
|
| Aspirin | 1 | 2017 | 121 | 0.120 |
Why?
|
| Insulin | 1 | 2018 | 484 | 0.120 |
Why?
|
| Benzylidene Compounds | 1 | 2016 | 4 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 853 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 149 | 0.120 |
Why?
|
| Aged | 4 | 2025 | 10142 | 0.120 |
Why?
|
| Molecular Structure | 3 | 2021 | 315 | 0.110 |
Why?
|
| Proteasome Inhibitors | 1 | 2014 | 101 | 0.110 |
Why?
|
| Amyloid beta-Peptides | 3 | 2021 | 65 | 0.110 |
Why?
|
| Proteomics | 3 | 2025 | 325 | 0.100 |
Why?
|
| Male | 6 | 2025 | 26652 | 0.100 |
Why?
|
| Computer Simulation | 3 | 2018 | 292 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 1368 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 3 | 2016 | 108 | 0.090 |
Why?
|
| RNA Interference | 3 | 2016 | 185 | 0.090 |
Why?
|
| Female | 5 | 2025 | 28055 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2025 | 1467 | 0.080 |
Why?
|
| Obesity | 1 | 2018 | 1183 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 136 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 624 | 0.080 |
Why?
|
| Thermodynamics | 2 | 2021 | 34 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2021 | 207 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2020 | 237 | 0.070 |
Why?
|
| Neurofibrillary Tangles | 1 | 2025 | 6 | 0.060 |
Why?
|
| Mitochondrial Dynamics | 1 | 2025 | 22 | 0.060 |
Why?
|
| Cell Death | 2 | 2016 | 169 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 3382 | 0.050 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2023 | 16 | 0.050 |
Why?
|
| Guanosine Triphosphate | 1 | 2023 | 15 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2023 | 104 | 0.050 |
Why?
|
| Tubulin | 1 | 2023 | 22 | 0.050 |
Why?
|
| Microtubules | 1 | 2023 | 34 | 0.050 |
Why?
|
| Exosomes | 1 | 2023 | 56 | 0.050 |
Why?
|
| Electrophorus | 1 | 2021 | 5 | 0.050 |
Why?
|
| Butyrylcholinesterase | 1 | 2021 | 8 | 0.040 |
Why?
|
| Acetylcholinesterase | 1 | 2021 | 20 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 32 | 0.040 |
Why?
|
| Lactones | 1 | 2021 | 25 | 0.040 |
Why?
|
| Horses | 1 | 2021 | 48 | 0.040 |
Why?
|
| Protein Folding | 1 | 2021 | 60 | 0.040 |
Why?
|
| Myocardium | 1 | 2023 | 477 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 124 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2020 | 11 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2020 | 62 | 0.040 |
Why?
|
| Glioma | 1 | 2021 | 77 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 134 | 0.040 |
Why?
|
| Xenopus laevis | 1 | 2019 | 44 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2019 | 71 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 169 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 102 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 273 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 343 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 2018 | 35 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2018 | 52 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 35 | 0.040 |
Why?
|
| Mutant Proteins | 1 | 2018 | 35 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 459 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 424 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 1872 | 0.040 |
Why?
|
| Drug Design | 1 | 2018 | 121 | 0.040 |
Why?
|
| Actins | 1 | 2018 | 117 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 618 | 0.030 |
Why?
|
| Apolipoprotein E3 | 1 | 2017 | 9 | 0.030 |
Why?
|
| Bacteria | 1 | 2019 | 220 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 19 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2017 | 29 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2017 | 71 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2017 | 73 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 371 | 0.030 |
Why?
|
| Acetylation | 1 | 2017 | 96 | 0.030 |
Why?
|
| Peptides | 1 | 2018 | 234 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 560 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2018 | 316 | 0.030 |
Why?
|
| Intermediate Filament Proteins | 1 | 2016 | 12 | 0.030 |
Why?
|
| Detergents | 1 | 2016 | 15 | 0.030 |
Why?
|
| tau Proteins | 1 | 2016 | 25 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 28 | 0.030 |
Why?
|
| Solubility | 1 | 2016 | 81 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 563 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 206 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 119 | 0.030 |
Why?
|
| Lipids | 1 | 2016 | 159 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 216 | 0.030 |
Why?
|
| Adult | 2 | 2024 | 14095 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 109 | 0.030 |
Why?
|
| Fertility | 1 | 2014 | 32 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 57 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 866 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 621 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1135 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 796 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 588 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1193 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1199 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 4307 | 0.020 |
Why?
|
| Middle Aged | 1 | 2016 | 13028 | 0.010 |
Why?
|